ESMO 2021 Lung Cancer – Natasha B. Leighl

Natasha B. Leighl outlines recent insights gained in terms of circulating tumor DNA in patients with advanced NSCLC, the impact of liquid biopsy on the time to treatment, advantages of complementary testing, the clinical utility of plasma ctDNA testing in the context of treatment monitoring and future first-line treatment options for patients with advanced NSCLC.

Here is the full ESMO 2021 Lung Cancer report.